No wonder most people were put off and thought Ellis mad for doing it' (Marks 2006)
Trials with older GLP-1 drugs (liraglutide, exenatide) including the large ADJUNCT ONE and ADJUNCT TWO studies showed modest HbA1c improvements of 0.10.7%, meaningful weight loss, and lower insulin requirements, but also raised early concerns about hypoglycemia and ketosis that kept enthusiasm in check for years
[70] have found that GLP-1 directly acts on LXR in liver cells to mediate cholesterol outflow
When prescribed and monitored by a qualified healthcare provider, these medications can: Improve insulin sensitivity Reduce appetite and food cravings Support weight loss in certain patients However, outside of a controlled medical environmen t, these effects can become unpredictable and even dangerous
One of the most notable effects is delayed gastric emptying, which contributes to decreased postprandial glucose peaks and increased satiety